Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
ApexOnco Front Page
Recent articles
Inclacumab fails, and osivelotor is on hold.
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The move comes after a death in the Alpha-3 cema-cel study.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
